Payment overview · 2025
General Payments
$1,530.11
98 reported records · 22 companies
Healthcare provider profile · identity verified
David Willis Baker, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · HOOKERTON, NC · NPI 1942596481
Verified facts
What the public records show
CMS Open Payments records show David Willis Baker, M.D. received $1,530.11 in general payments during 2025 across 98 reported records.
ABBVIE INC. accounted for 22.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Linzess, Mounjaro, Ozempic, Trelegy Ellipta, Trintellix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 123 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 206 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $336.29 | 22.0% | 24 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $201.47 | 13.2% | 9 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $150.43 | 9.8% | 15 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $135.12 | 8.8% | 9 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $86.03 | 5.6% | 5 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $69.55 | 4.5% | 4 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $65.66 | 4.3% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $59.94 | 3.9% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $50.17 | 3.3% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $45.84 | 3.0% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $42.39 | 2.8% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $38.77 | 2.5% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $38.51 | 2.5% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $33.42 | 2.2% | 2 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $32.32 | 2.1% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $32.12 | 2.1% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $28.80 | 1.9% | 2 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $23.91 | 1.6% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.32 | 1.1% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $14.75 | 1.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.37 | 0.9% | 1 | 2025 |
| Verity Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $13.93 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,530.11 | 98 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $201.47 | 9 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $150.43 | 15 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $150.43 | 15 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $127.38 | 11 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $108.77 | 7 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $98.30 | 6 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $86.03 | 5 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $77.44 | 5 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $77.44 | 5 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $69.55 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $67.52 | 3 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $65.66 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $59.94 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $50.17 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $45.84 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $38.77 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $38.51 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $36.82 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $36.82 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $33.42 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $33.42 | 2 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $32.32 | 2 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $32.32 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $32.12 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $28.80 | 2 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $23.91 | 1 | 2025 |
Source payment records
|
|||||
| PROCLAIM Normalized: proclaim |
Device | Abbott Laboratories | $23.86 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $18.53 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $17.81 | 1 | 2025 |
Source payment records
|
|||||
| EDARBI Normalized: edarbi |
Drug | Azurity Pharmaceuticals, Inc. | $16.32 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $14.75 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.37 | 1 | 2025 |
Source payment records
|
|||||
| Tlando Normalized: tlando |
Drug | Verity Pharmaceuticals Inc. | $13.93 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 41 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 51 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 107 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 123 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 95 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
107 | 21 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
41 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
18 | 18 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
66 | 54 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
95 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
123 | 22 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
206 | 39 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 495 | 124 |
| Omeprazole | Omeprazole | 423 | 102 |
| Amlodipine Besylate | Amlodipine Besylate | 420 | 106 |
| Levothyroxine Sodium | Levothyroxine Sodium | 388 | 87 |
| Gabapentin | Gabapentin | 349 | 86 |
| Lisinopril | Lisinopril | 299 | 74 |
| Trazodone Hcl | Trazodone Hcl | 267 | 56 |
| Pantoprazole Sodium | Pantoprazole Sodium | 260 | 61 |
| Furosemide | Furosemide | 253 | 71 |
| Zolpidem Tartrate | Zolpidem Tartrate | 240 | 38 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 230 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 226 | 57 |
| Losartan Potassium | Losartan Potassium | 215 | 63 |
| Prednisone | Prednisone | 215 | 120 |
| Eliquis | Apixaban | 206 | 39 |
| Alprazolam | Alprazolam | 203 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 196 | 45 |
| Potassium Chloride | Potassium Chloride | 193 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 187 | 48 |
| Tramadol Hcl | Tramadol Hcl | 185 | 48 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 184 | 55 |
| Montelukast Sodium | Montelukast Sodium | 173 | 47 |
| Metformin Hcl | Metformin Hcl | 169 | 48 |
| Meloxicam | Meloxicam | 163 | 28 |
| Famotidine | Famotidine | 154 | 34 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 143 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 139 | 46 |
| Oxycodone Hcl | Oxycodone Hcl | 138 | 30 |
| Azithromycin | Azithromycin | 128 | 101 |
| Pregabalin | Pregabalin | 128 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 127 | 29 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 126 | 35 |
| Ozempic | Semaglutide | 123 | 22 |
| Sertraline Hcl | Sertraline Hcl | 123 | 29 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 120 | 90 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 119 | 83 |
| Clopidogrel | Clopidogrel Bisulfate | 115 | 22 |
| Linzess | Linaclotide | 107 | 21 |
| Simvastatin | Simvastatin | 107 | 24 |
| Allopurinol | Allopurinol | 103 | 27 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 102 | 36 |
| Carvedilol | Carvedilol | 101 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 100 | 27 |
| Metformin Hcl Er | Metformin Hcl | 100 | 23 |
| Fluconazole | Fluconazole | 99 | 64 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 95 | 28 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 91 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 89 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 88 | 24 |
| Diclofenac Sodium | Diclofenac Sodium | 79 | 35 |
| Amoxicillin | Amoxicillin | 78 | 53 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 72 | 23 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 72 | 14 |
| Mirtazapine | Mirtazapine | 72 | 23 |
| Ondansetron Odt | Ondansetron | 71 | 39 |
| Pravastatin Sodium | Pravastatin Sodium | 70 | 18 |
| Atenolol | Atenolol | 69 | 18 |
| Donepezil Hcl | Donepezil Hcl | 68 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 67 | 23 |
| Doxycycline Hyclate | Doxycycline Hyclate | 66 | 50 |
| Glipizide | Glipizide | 66 | 14 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 66 | 54 |
| Finasteride | Finasteride | 65 | 13 |
| Lorazepam | Lorazepam | 63 | 34 |
| Methocarbamol | Methocarbamol | 60 | 28 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 60 | 34 |
| Nortriptyline Hcl | Nortriptyline Hcl | 59 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 59 | suppressed |
| Ibuprofen | Ibuprofen | 57 | 22 |
| Baclofen | Baclofen | 56 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 56 | 16 |
| Meclizine Hcl | Meclizine Hcl | 56 | 21 |
| Ventolin Hfa | Albuterol Sulfate | 56 | 20 |
| Xarelto | Rivaroxaban | 56 | suppressed |
| Bumetanide | Bumetanide | 55 | 14 |
| Buspirone Hcl | Buspirone Hcl | 53 | 11 |
| Mupirocin | Mupirocin | 52 | 28 |
| Jardiance | Empagliflozin | 51 | suppressed |
| Bupropion Xl | Bupropion Hcl | 49 | 11 |
| Spironolactone | Spironolactone | 48 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 47 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 47 | 11 |
| Temazepam | Temazepam | 44 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 43 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | 11 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 42 | 42 |
| Cephalexin | Cephalexin | 42 | 30 |
| Farxiga | Dapagliflozin Propanediol | 41 | 11 |
| Glipizide Er | Glipizide | 41 | suppressed |
| Lovastatin | Lovastatin | 41 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 40 | suppressed |
| Cilostazol | Cilostazol | 39 | suppressed |
| Clonazepam | Clonazepam | 39 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 38 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 36 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 35 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 35 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 35 | suppressed |
| Colchicine | Colchicine | 34 | 13 |
| Divalproex Sodium | Divalproex Sodium | 34 | suppressed |
| Levofloxacin | Levofloxacin | 34 | 28 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 34 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 34 | 13 |
| Myrbetriq | Mirabegron | 33 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 32 | suppressed |
| Glimepiride | Glimepiride | 32 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 32 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | suppressed |
| Belsomra | Suvorexant | 31 | 16 |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 31 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 31 | suppressed |
| Sucralfate | Sucralfate | 31 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | suppressed |
| Repatha Sureclick | Evolocumab | 30 | suppressed |
| Risperidone | Risperidone | 30 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 29 | 22 |
| Ibu | Ibuprofen | 29 | 14 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 28 | 16 |
| Methylprednisolone | Methylprednisolone | 28 | 22 |
| Topiramate | Topiramate | 28 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 27 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 26 | suppressed |
| Ezetimibe | Ezetimibe | 26 | suppressed |
| Ketoconazole | Ketoconazole | 26 | 21 |
| Mounjaro | Tirzepatide | 26 | suppressed |
| Nystatin | Nystatin | 26 | 24 |
| Valsartan | Valsartan | 26 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 25 | 16 |
| Nifedipine Er | Nifedipine | 24 | suppressed |
| Xtampza Er | Oxycodone Myristate | 24 | suppressed |
| Cefdinir | Cefdinir | 23 | 21 |
| Invega Sustenna | Paliperidone Palmitate | 23 | suppressed |
| Trulicity | Dulaglutide | 23 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 22 | suppressed |
| Estradiol | Estradiol | 22 | suppressed |
| Methotrexate | Methotrexate Sodium | 22 | suppressed |
| Risperdal Consta | Risperidone Microspheres | 22 | suppressed |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Armour Thyroid | Thyroid,pork | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 21 | 13 |
| Entresto | Sacubitril/Valsartan | 21 | suppressed |
| Haloperidol | Haloperidol | 21 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 21 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Dexamethasone | Dexamethasone | 20 | 20 |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Testosterone | Testosterone | 20 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 18 | 18 |
| Carbamazepine Er | Carbamazepine | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Brilinta | Ticagrelor | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 15 |
| Torsemide | Torsemide | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Fentanyl | Fentanyl | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Tobramycin | Tobramycin | 15 | 13 |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 14 | suppressed |
| Butorphanol Tartrate | Butorphanol Tartrate | 14 | suppressed |
| Carisoprodol | Carisoprodol | 14 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Movantik | Naloxegol Oxalate | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 14 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Guanfacine Hcl Er | Guanfacine Hcl | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | 12 |
| Naproxen | Naproxen | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 12 | suppressed |
| Motegrity | Prucalopride Succinate | 12 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 12 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Amantadine | Amantadine Hcl | 11 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Haloperidol Lactate | Haloperidol Lactate | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,530.11 · 98 records | ABBVIE INC. | CAPLYTA, CREON, Cologuard Collection Kit, Dexcom G6 Transmitter, EDARBI, FARXIGA, FREESTYLE LIBRE 3, Fluad, Flucelvax, IBSRELA, JARDIANCE, Kerendia, LINZESS, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PROCLAIM, QULIPTA, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, TRINTELLIX, Tlando, UBRELVY, VRAYLAR, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND, ZORYVE, ZTLido | 18 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error